Ireland - English - HPRA (Health Products Regulatory Authority)

hameln pharma gmbh - voriconazole - powder for solution for infusion - voriconazole

Australia - English - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - hydromorphone-hameln and hydromorphone-hameln-hp injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium citrate dihydrate; sodium hydroxide; hydrochloric acid; sodium chloride - hydromorphone-hameln and hydromorphone-hameln-hp injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Israel - English - Ministry of Health

pharma medis - ketamine as hydrochloride - solution for injection / infusion - ketamine as hydrochloride 50 mg/ml - ketamine - as the sole anaesthetic agent for diagnostic and surgical procedures. when used by intravenous or intramuscular injection, ketamine-hameln is best suited for short procedures. with additional doses, or by intravenous infusion, ketamine-hameln can be used for longer procedures. if skeletal muscle relaxation is desired, a muscle relaxant should be used and respiration should be supported.for the induction of anesthesia prior to the administration of other general anesthetic agents.to supplement other anesthetic agents.specific areas of application or types of procedures:when the intramuscular route of administration is preferred.debridement, painful dressings, and skin grafting in burned patients, as well as other superficial surgical procedures.neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms, and lumbar punctures.diagnostic and operative procedures of the eye, ear, nose, and mouth, including dental extractions.note: eye movements may persist during ophthalmological procedures. anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided, if at all possible. orthopaedic procedures such as closed reductions, manipulations, femoral pinning, amputations, and biopsies. sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. cardiac catheterization procedures.caesarian section; as an induction agent in the absence of elevated blood pressure. anaesthesia in the asthmatic patient, either to minimise the risks of an attack of bronchospasm developing, or in the presence of bronchospasm where anaesthesia cannot be delayed.

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - geranium robertianum (unii: r5i1hk0ubl) (geranium robertianum - unii:r5i1hk0ubl), rorippa nasturtium-aquaticum (unii: yh89gmv676) (rorippa nasturtium-aquaticum - unii:yh89gmv676), ferrous iodide (unii: f5452u54pn) (ferrous iodide - unii:f5452u54pn), juglans regia flowering top (unii: 3ba2n709ng) (juglans regia flowering top - unii:3ba2n709ng), myosotis arvensis (unii: c73bk97h5j) (myosotis arvensis - unii:c73bk97h5j), scrophularia nodosa (unii: 7h443nub2t) (scrophularia nodosa - unii:7h443nub2t), teuc - geranium robertianum 4 [hp_x] in 1.1 ml - injection solution ingredient information: each 1.1ml ampule contains: geranium robertianum 4x 1.1 mcl, nasturtium aquaticum 4x 1.1 mcl, ferrum iodatum 12x 1.1 mcl, juglans regia 3x 0.55 mcl, myosotis arvensis 3x 0.55 mcl, scrophularia nodosa 3x 0.55 mcl, teucrium scorodonia 3x 0.55 mcl, veronica officinalis 3x 0.55 mcl, equistetum hyemale 4x 0.55 mcl, fumaria officinalis 4x 0.55 mcl, natrum sulphuricum 4x 0.55 mcl, pinus sylvestris 4x 0.55 mcl, gentiana lutea 5x 0.55 mcl, aranea diadema 6x 0.55 mcl, sarsaparilla 6x 0.55 mcl, calcarea phosphorica 12x 0.55 mcl, levothyroxine 12x 0.55 mcl. inactive ingredients: sterile isotonic sodium chloride solution.

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - pentetate calcium trisodium (unii: g79yn26h5b) (pentetic acid - unii:7a314hqm0i) - pentetate calcium trisodium 1000 mg in 5 ml - ca-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none. pregnancy category c risk summary there are no adequate and well-controlled studies of ca-dtpa use in pregnant women. ca-dtpa chelation therapy causes depletion of body stores of zinc, a trace metal essential for fetal development [see warnings and precautions (5.2)] . the consequences of zinc depletion and results of animal studies suggest a teratogenic risk in humans. ca-dtpa was teratogenic and embryotoxic in mice at daily doses 2 to 8 times the recommended daily human dose, based on body surface area (bsa), with a dose-dependent increase in the frequency of gross malformations. ca-dtpa was teratogenic in dogs at approximately half the recommended daily human dose based on bsa, as described below. there are no animal or human data evaluating the teratogenic effect of a single dose of ca-dtpa. ca-dtpa should be used during pregnancy

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd) - aconitum napellus 6 [hp_x] in 1.1 ml

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw) - arnica montana 4 [hp_x] in 2.0 ml

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - pentetate zinc trisodium 1000 mg in 5 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none. pregnancy category b risk summary there are no adequate and well-controlled studies of zn-dtpa use in pregnant women. chelation treatment of pregnant women should begin and continue with zn-dtpa. reproduction studies have been performed in pregnant mice at doses up to 31 times (11.5 mmol/kg) the recommended daily human dose and have revealed no evidence of impaired fertility or harm to the fetus due to zn-dtpa. there was a slight reduction in the average birth weight. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. it is not known whether zn-dtpa is excreted in human milk. radiocontaminants are known to be excreted in breast milk. women with known or suspected internal contamination with radiocontaminants should not breast feed, whether

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

hameln pharma gmbh - remifentanilo (clorhidrato) - remifentanilo (clorhidrato)....5 mg